2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Fatty Acid Synthase (FASN)

Fatty Acid Synthase (FASN)

Fatty Acid Synthase (FASN)

Related Products

PDF 0.46 MB

Fatty Acid Synthase (FASN) is a multifunctional homodimeric enzyme protein, and it is the major enzyme required for the anabolic conversion of dietary carbohydrates to fatty acids. Fatty acid synthase catalyzes the conversion of acetyl-CoA and malonyl-CoA, in the presence of NADPH, into long-chain saturated fatty acids.

Human fatty acid synthase is a large homodimeric multifunctional enzyme that synthesizes palmitic acid. The unique carboxyl terminal thioesterase domain of fatty acid synthase hydrolyzes the growing fatty acid chain and plays a critical role in regulating the chain length of fatty acid released. Also, the up-regulation of human fatty acid synthase in a variety of cancer makes the thioesterase a candidate target for therapeutic treatment.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-110028
    Leelamine hydrochloride
    		Inhibitor 99.06%
    Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees. Leelamine hydrochloride is a cannabinoid receptor type 1 (CB1) agonist and a inhibitor of SREBP1-regulated fatty acid/lipid synthesis in prostate cancer cells that is not affected by androgen receptor status. Leelamine hydrochloride suppresses transcriptional activity of androgen receptor, which is known to regulate fatty acid synthesis[2,3].
    Leelamine hydrochloride
  • HY-N0686
    Pseudoprotodioscin
    		Inhibitor 98.76%
    Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides.
    Pseudoprotodioscin
  • HY-121250
    Fasnall
    		Inhibitor ≥98.0%
    Fasnall is a selective fatty acid synthase (FASN) inhibitor with an IC50 of 3.71 μM. Fasnall induces apoptosis in HER2+ breast cancer cell lines. Fasnall shows potent anti-tumor activities.
    Fasnall
  • HY-16207
    FGH10019
    		Inhibitor 99.87%
    FGH10019 is a novel sterol regulatory element-binding protein (SREBP) inhibitor with IC50 of 1 μM.
    FGH10019
  • HY-17640
    Nicodicosapent
    		Inhibitor 98.04%
    Nicodicosapent is a fatty acid niacin conjugate that is also an inhibitor of the sterol regulatory element binding protein (SREBP), a key regulator of cholesterol metabolism proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase, and NPC1L1.
    Nicodicosapent
  • HY-110354
    UCM05
    		Inhibitor 99.58%
    UCM05 (G28UCM) is a potent inhibitor of fatty acid synthase (FASN) shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines. UCM05 is a Filamentous temperature-sensitive protein Z (FtsZ) inhibitor and inhibits the growth of the Gram-positive bacterium B. subtilis with MIC values of 100 μM but lack activity on the Gram-negative bacterium E. coli.
    UCM05
  • HY-N0458
    Pedunculoside
    		Modulator 99.17%
    Pedunculoside exerts lipid-lowering effects partly through the regulation of lipogenesis and fatty acid β-oxidation.
    Pedunculoside
  • HY-12648
    FASN-IN-4
    		Inhibitor 99.21%
    FASN-IN-4 is a potent inhibitor of fatty acid synthase (FASN) with an IC50 of 10 nM (WO2012064642A1, compound 29). FASN-IN-4 also inhibits SARS-CoV-2 with an EC50 of 18.6 nM.
    FASN-IN-4
  • HY-B0218R
    Orlistat (Standard)
    		Inhibitor 99.85%
    Orlistat (Standard) is the analytical standard of Orlistat. This product is intended for research and analytical applications. Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity.?Anti-atherosclerotic?effect.
    Orlistat (Standard)
  • HY-111777
    FASN-IN-1
    		Inhibitor 99.90%
    FASN-IN-1 is a fatty acid synthase (FASN) inhibitor extracted from patent WO2015134790A1, compound 56.
    FASN-IN-1
  • HY-117769
    GSK837149A
    		Inhibitor ≥99.0%
    GSK837149A is a selective inhibitor of human Fatty Acid Synthase (FASN) targeting the KR domain. GSK837149A has reversible inhibition effect on FASN and selectivity for type I FASN (Ki=30 nM). GSK837149A is also a competitive inhibitor of NADPH and a non-competitive inhibitor of acetoacetyl-CoA. GSK837149A can be used for the research of obesity and breast cancer.
    GSK837149A
  • HY-N0082
    Praeruptorin B
    		Inhibitor 99.95%
    Praeruptorin B is an inhibitor of sterol regulatory element-binding proteins (SREBPs).
    Praeruptorin B
  • HY-P99133
    Anti-Mouse Fas Ligand Antibody (MFL3)
    		Inhibitor
    Anti-Mouse Fas Ligand Antibody is an anti-mouse Fas Ligand IgG antibody inhibitor derived from host Armenian Hamster.
    Anti-Mouse Fas Ligand Antibody (MFL3)
  • HY-145809
    FASN-IN-5
    		Inhibitor 99.81%
    FASN-IN-5 (example 11), a FASN inhibitor, can be used for the research of TH17- or CSF1 -mediated disease or disorder such as cancer, immunological disorders, and obesity.
    FASN-IN-5
  • HY-128851B
    Coenzyme A sodium
    		Chemical
    Coenzyme A (CoASH) sodium is a ubiquitous and essential cofactor, which is an acyl group carrier and carbonyl-activating group for the citric acid cycle and fatty acid metabolism. Coenzyme A plays a central role in the oxidation of pyruvate in the citric acid cycle and the metabolism of carboxylic acids, including short- and long-chain fatty acids.
    Coenzyme A sodium
  • HY-149540
    CTL-06
    		Inhibitor
    CTL-06 is an inhibitor of Fatty Acid Synthase (FASN) (IC50: 3 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research.
    CTL-06
  • HY-U00436
    FASN-IN-3
    		Inhibitor 98.17%
    FASN-IN-3 is a fatty acid synthase (FASN) inhibitor extracted from patent US20170119786A1, compound 242A.
    FASN-IN-3
  • HY-13447
    PF-429242
    		Inhibitor
    PF429242 is a reversible and competitive SREBP site 1 protease (S1P) inhibitor with an IC50 of 175 nM.
    PF-429242
  • HY-155282
    FASN-IN-6
    		Inhibitor
    FASN-IN-6 (compound 44) is a potent fatty acid biosynthesis (FAB) inhibitor. FASN-IN-6 is an antibacterial agent with MICs of 1 μg/mL and 4 μg/mL for S. aureus ATCC 25923 and E. faecalis ATCC 29212, respectively.
    FASN-IN-6
  • HY-12364B
    (−)-C75
    		Inhibitor
    (−)-C75 is a isoform of C75 (HY-12364), which is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM. C75 is a potent CPT1A activator.
    (−)-C75
Cat. No. Product Name / Synonyms Application Reactivity